The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

Initiatives to eradicate malaria have a good impact on P. falciparum malaria worldwide. P.
vivax, however, still presents significant difficulties. This is due to its unique biological traits …

Low glucose-6-phosphate dehydrogenase enzyme (G6PD) activity is a key determinant of
drug-induced haemolysis. More than 230 clinically relevant genetic variants have been …

Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-
Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8 …

The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest
challenges for achieving malaria elimination from the Asia–Pacific by 2030. During the …

Background Point-of-care glucose-6-phosphate dehydrogenase (G6PD) testing has the
potential to make the use of radical treatment for vivax malaria safer and more effective …

The goal to eliminate malaria from the Asia-Pacific by 2030 will require the safe and
widespread delivery of effective radical cure of malaria. In October 2017, the Asia Pacific …

Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not
routinely performed before primaquine treatment in most Plasmodium vivax endemic areas …

Background Wide-spread implementation of treatment regimens for the radical cure of vivax
malaria is hindered by a range of factors. This has resulted in an increase in the relative …

Background The changing global health landscape has highlighted the need for more
proactive, efficient and transparent health policy-making. After more than 60 years of limited …